Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma

BACKGROUND: Rituximab plus CHOP (R-CHOP) significantly improved the outcome of diffuse large B cell lymphoma (DLBCL), a common sub-type of non-Hodgkin lymphoma. But 40% – 50% of DLBCL patients cannot be cured by this regimen. Some clinical trials showed that bevacizumab might be useful in the treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Zhiying, Zhu, Jun, Zheng, Wen, Liu, Weiping, Ying, Zhitao, Xie, Yan, Wang, Xiaopei, Lin, Ningjing, Tu, Meifeng, Ping, Lingyan, Deng, Lijuan, Zhang, Chen, Ding, Ning, Song, Yuqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897913/
https://www.ncbi.nlm.nih.gov/pubmed/24438119
http://dx.doi.org/10.1186/1475-2867-14-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897913/
https://www.ncbi.nlm.nih.gov/pubmed/24438119
http://dx.doi.org/10.1186/1475-2867-14-5

Ejemplares similares